Author: admin

Pocket Entertainment Elevates Umesh Bude to CTO, Accelerating Its Vision as an AI Entertainment Leader

“Umesh has been instrumental in scaling Pocket Entertainment’s tech stack from the ground up.”

Los Angeles, California – June 17, 2025 – Pocket Entertainment, the parent company behind Pocket FM, Pocket Toons, and Pocket Novel, has announced the elevation of Umesh Bude to Chief Technology Officer (CTO). Previously Senior Vice President of Engineering, Umesh will now spearhead the company’s technology vision, with a sharp focus on building the future of AI-powered storytelling.

As CTO, Umesh will lead the end-to-end tech strategy across all platforms under Pocket Entertainment, anchoring efforts to scale its global products through next-gen AI solutions. His mandate includes building seamless user experiences, advancing generative AI capabilities, and ensuring tech-led innovation across the board.

Commenting on his new role, Bude said, “It’s a privilege to take on this responsibility at such an exciting time for Pocket Entertainment. I look forward to driving the next wave of innovation, where technology and AI are not just enablers, but storytellers in their own right.”

Bude will continue reporting to Prateek Dixit as the company strengthens its position at the intersection of entertainment and technology.

“We are at a pivotal moment in our journey where technology and creativity are deeply intertwined. As we reimagine storytelling for the AI era, technology is the foundation,” said Dixit, Co-founder of Pocket Entertainment. “Umesh’s elevation is a reflection of our ambition to lead this transformation from the front. His leadership will be central to creating intelligent, emotionally aware experiences that push the boundaries of what storytelling can be.”

With close to two decades of experience across engineering, data science, and platform security, Umesh has been instrumental in scaling Pocket Entertainment’s tech stack from the ground up. Under his leadership, the company will continue to pioneer responsible and disruptive innovations in AI, turning technology into a creative force that empowers both our storytellers and audiences.

About Pocket Entertainment

Pocket Entertainment is a global leader in digital storytelling, pioneering the future of immersive content experiences. As the parent company of Pocket FM, Pocket Novel, and now Pocket Toons, it is redefining entertainment across audio, literature, and visual storytelling. With a bold vision to unleash human creativity through AI, Pocket Entertainment empowers storytellers with cutting-edge technology that enhances, rather than replaces, artistic expression. By blending AI-driven efficiencies with human imagination, the company is revolutionizing how stories are created, distributed, and consumed at scale.

Media Contact
Company Name: Pocket FM
Email: Send Email
Country: United States
Website: https://pocketfm.com/us

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pocket Entertainment Elevates Umesh Bude to CTO, Accelerating Its Vision as an AI Entertainment Leader

Periodontal Inflammation Market Expected to Experience Major Growth by 2032, According to DelveInsight | Geistlich Pharma AG, Noveome Biotherapeutics, Amyndas Pharmaceuticals

The Key Periodontal Inflammation Companies in the market include – Geistlich Pharma AG, Noveome Biotherapeutics, Amyndas Pharmaceuticals, and others.

 

The Periodontal Inflammation market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Periodontal Inflammation pipeline products will significantly revolutionize the Periodontal Inflammation market dynamics.

 

DelveInsight’s “Periodontal Inflammation Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Periodontal Inflammation, historical and forecasted epidemiology as well as the Periodontal Inflammation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Periodontal Inflammation market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Periodontal Inflammation market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Periodontal Inflammation Market Forecast

 

Some of the key facts of the Periodontal Inflammation Market Report:

  • The Periodontal Inflammation market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • According to the Centers for Disease Control and Prevention (CDC), almost 50 percent of adults in the US, over the age of 30, have the advanced form of Periodontal Inflammation, or gum disease. The data confirmed that gum disease is prevalent in the United States. Americans bear a very heavy burden when it comes to Periodontal Inflammation

  • In a study by Abe et al. (2022), Periodontal Inflammation is currently the leading cause (40.4% in men and 34.9% in women), surpassing caries (30.2% in men and 29.0% in women)

  • Key Periodontal Inflammation Companies: Geistlich Pharma AG, Noveome Biotherapeutics, Amyndas Pharmaceuticals, and others

  • Key Periodontal Inflammation Therapies: PerioSept(r), ST266, AMY 101, and others

  • The Periodontal Inflammation epidemiology based on gender analyzed that males are slightly more affected in the case of Periodontal Inflammation

 

Periodontal Inflammation Overview

Periodontal inflammation is the body’s immune response to harmful bacteria in the gums. It occurs when plaque builds up around the teeth, causing redness, swelling, and bleeding of the gums. If left untreated, it can progress to periodontitis, a serious gum disease that may lead to tooth loss and bone damage.

 

Get a Free sample for the Periodontal Inflammation Market Report

https://www.delveinsight.com/report-store/periodontal-inflammation-market

 

Periodontal Inflammation Market

The dynamics of the Periodontal Inflammation market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2019-2032.

“Large proportions of patients require care for Periodontal Inflammation and operative management of caries. While there is no significant difference between preventive treatment planned and received, there are significant differences in treatment planned and received for all types of restorative care.”

 

Periodontal Inflammation Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Periodontal Inflammation Epidemiology Segmentation:

The Periodontal Inflammation market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Periodontal Inflammation

  • Prevalent Cases of Periodontal Inflammation by severity

  • Gender-specific Prevalence of Periodontal Inflammation

  • Diagnosed Cases of Episodic and Chronic Periodontal Inflammation

 

Download the report to understand which factors are driving Periodontal Inflammation epidemiology trends @ Periodontal Inflammation Epidemiological Insights

 

Periodontal Inflammation Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Periodontal Inflammation market or expected to get launched during the study period. The analysis covers Periodontal Inflammation market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Periodontal Inflammation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Periodontal Inflammation Therapies and Key Companies

  • PerioSept(r): Geistlich Pharma AG

  • ST266: Noveome Biotherapeutics

  • AMY 101: Amyndas Pharmaceuticals

 

To know more about Periodontal Inflammation treatment, visit @ Periodontal Inflammation Medications

 

Periodontal Inflammation Market Strengths

  • Late-stage pipeline drugs such as Faricimab, Beovu and KSI-301 are some of the potential emerging therapies that have shown promising results and expected to improve the dosing interval

 

Periodontal Inflammation Market Unmet Needs

  • Need of novel and effective treatment for Periodontal Inflammation

  • Need to develop management guidelines for adolescents and adults with Periodontal Inflammation

  • Need for reassessment of doses for Periodontal Inflammation

 

Scope of the Periodontal Inflammation Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Periodontal Inflammation Companies: Geistlich Pharma AG, Noveome Biotherapeutics, Amyndas Pharmaceuticals, and others

  • Key Periodontal Inflammation Therapies: PerioSept(r), ST266, AMY 101, and others

  • Periodontal Inflammation Therapeutic Assessment: Periodontal Inflammation current marketed and Periodontal Inflammation emerging therapies

  • Periodontal Inflammation Market Dynamics: Periodontal Inflammation market drivers and Periodontal Inflammation market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Periodontal Inflammation Unmet Needs, KOL’s views, Analyst’s views, Periodontal Inflammation Market Access and Reimbursement

 

Discover more about therapies set to grab major Periodontal Inflammation market share @ Periodontal Inflammation Treatment Landscape

 

Table of Contents

1. Periodontal Inflammation Market Report Introduction

2. Executive Summary for Periodontal Inflammation

3. SWOT analysis of Periodontal Inflammation

4. Periodontal Inflammation Patient Share (%) Overview at a Glance

5. Periodontal Inflammation Market Overview at a Glance

6. Periodontal Inflammation Disease Background and Overview

7. Periodontal Inflammation Epidemiology and Patient Population

8. Country-Specific Patient Population of Periodontal Inflammation

9. Periodontal Inflammation Current Treatment and Medical Practices

10. Periodontal Inflammation Unmet Needs

11. Periodontal Inflammation Emerging Therapies

12. Periodontal Inflammation Market Outlook

13. Country-Wise Periodontal Inflammation Market Analysis (2019–2032)

14. Periodontal Inflammation Market Access and Reimbursement of Therapies

15. Periodontal Inflammation Market Drivers

16. Periodontal Inflammation Market Barriers

17. Periodontal Inflammation Appendix

18. Periodontal Inflammation Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Periodontal Inflammation Market Expected to Experience Major Growth by 2032, According to DelveInsight | Geistlich Pharma AG, Noveome Biotherapeutics, Amyndas Pharmaceuticals

Zarai Maza Emerges as a Hemispheric Leader in Human Rights and Social Strategy.

Zarai Maza Emerges as a Hemispheric Leader in Human Rights and Social Strategy.

Zarai Maza Emerges as a Hemispheric Leader in Human Rights and Social Strategy at the OEA — The Organization of American States, based in Washington, D.C., unites 35 countries to promote democracy and human rights across the Americas.
With a presence across three continents, over 400 scholarships awarded, and a growing diplomatic agenda, Maza is redefining the role of civil society in the defense of fundamental rights.

Miami, FL – June 17, 2025 – In a global context marked by democratic fragility, forced displacement, and the erosion of fundamental freedoms, Zarai Maza has emerged as one of the most influential voices in the Western Hemisphere. Her work blends grassroots action, institutional development, and strategic presence in multilateral spaces, positioning her as a leader capable of connecting civil society with centers of political decision-making.

In March of this year, she was invited to speak at the Hall of the Americas at the Organization of American States (OAS), where she shared the panel with Secretary General Dr. Luis Almagro and other prominent guests during the Hispanic Voices for Human Rights Summit, organized by AMAVEX in collaboration with the OAS. Her speech, titled “Migrating as a Professional: The Emotional Challenge of Starting Over”, served as a powerful call to recognize the contribution of displaced professionals to the development of host countries.

Former OAS Secretary General Dr. Luis Almagro Honored at the Hispanic Voices for Human Rights Summit — AMAVEX Presents Award for His Legacy in Defending Human Rights, with Zarai Maza Among Distinguished Participants.

In July 2024, she was a panelist and co-sponsor of the Human Rights Summit at the United Nations Headquarters, invited by United for Human Rights. During the Human Rights in Action panel, she discussed the challenges of turning human rights into tangible realities and presented measurable results from her international campaigns. She also proposed a strategic collaboration model between governments and civil society for the coming decade.

Video Link: https://www.youtube.com/embed/aV2km-dJ6ro

As the founder and executive director of the Guardians of Human Rights Foundation, Maza has built an active network across more than 15 countries in the Americas, Asia, and Europe, leading programs focused on human rights education, youth leadership, women’s empowerment, and the prevention of violence and drug abuse. Under her leadership, the foundation has awarded more than 400 institutional scholarships in partnership with U.S. universities, helping migrants and refugees access master’s and bachelor’s degree programs.

Through its programs and campaigns, the foundation has reached more than 4.4 million people globally, mobilized over 5,620 human rights advocates, and maintains an active presence on three continents.

Maza’s journey has taken her from forums in India and Japan to multilateral platforms, local governments, and universities throughout the Americas and Europe. Her work has been recognized by the White House, the United States Congress, and multiple municipalities that have issued official proclamations in support of her awareness and education campaigns.

Maza leads not only through action, but also through vision. Her 2025–2030 agenda includes the launch of an International Youth Leadership Network, the establishment of Regional Human Rights Centers in Latin America and Asia, and the formal recognition of her foundation as a consultative actor before multilateral bodies.

Born in Venezuela and forced into exile in 2017, she has transformed her personal story into a platform for global action.

She no longer speaks solely as a witness to exile, but as a builder of solutions to the greatest human rights challenges of our time.

About Zarai Maza:

Zarai Maza is an international speaker, university professor, strategist, and the founder and executive director of the Guardians of Human Rights Foundation. She is widely recognized as one of the most prominent voices in the hemisphere on human rights. Maza has represented civil society in high-level forums such as the United Nations and the Organization of American States, and her work has been honored by the White House, the U.S. Congress, and local governments across the Americas and Europe. Her leadership has driven impactful programs in community empowerment, human rights education, youth leadership, violence prevention, and access to higher education for migrants and refugees. She is currently advancing a global agenda focused on empowering youth, fostering international cooperation, and defending fundamental rights in an increasingly complex world.

Zarai Maza Receives Lifetime Achievement Award from Christopher King, Founder of The Gentlemen’s Course, for Her Impactful Social Contributions Through Human Rights Awareness.

(Press Release by Reinaldo Vandres – PR Director)

Media Contact
Company Name: Guardians of Human Rights Foundation
Contact Person: Reinaldo Vandres – PR Director
Email: Send Email
Phone: +1 (727)-367-6895
City: Miami
State: Florida
Country: United States
Website: https://www.gohumanrights.com/

In-Home Fitness Trainer in Portland, OR Celebrates Decade of Success With Feature in National Redfin Blog

Portland, OR – EVOLVE Integrative Personal Training is marking ten years of fitness excellence with a prestigious feature in a national Redfin blog post. Since founding the company in 2015, owner Lisa Stein has expanded from a solo operation to a team of experienced trainers serving clients throughout the Portland metropolitan area.

The company has established itself as a leader in personal training in Portland, OR, offering customized programs that cater to individual needs, goals, and schedules. Their approach integrates various fitness methodologies with a focus on long-term wellness rather than short-term results.

Beyond standard training programs, EVOLVE Integrative Personal Training has developed a significant following for those looking for a private yoga instructor at home in Portland, OR. This offering has become particularly popular among clients seeking to improve flexibility, reduce stress, and enhance mind-body connection in the comfort of their own homes.

“The past decade has been an incredible journey of growth and transformation,” said Lisa Stein, Certified Personal Trainer and founder of EVOLVE Integrative Personal Training. “Being recognized by Redfin validates our client-centered approach and our commitment to meeting people exactly where they are in their fitness journey.”

The company has also seen substantial growth in their programs for corporate personal training in Portland, OR, providing wellness solutions for local businesses looking to improve employee health, productivity, and job satisfaction. These corporate partnerships have become an increasingly important part of EVOLVE’s service portfolio.

As they enter their second decade, EVOLVE Integrative Personal Training is expanding their reach with a new trainer in Austin, Texas. Additionally, their Virtual Strength and Balance class continues to serve clients who prefer remote options, demonstrating the company’s versatility beyond being an in-home fitness trainer in Portland, OR. This dual approach of in-person and virtual training has proven highly effective for clients with varying schedules and preferences.

For Portland residents looking to transform their fitness routine with personalized, in-home training, visit https://www.evolvetogetherpdx.com/services.html to schedule a consultation and join the hundreds of satisfied clients who have achieved their health goals with EVOLVE Integrative Personal Training.

Media Contact
Company Name: EVOLVE Intergative Personal Training
Contact Person: Lisa Stein
Email: Send Email
Phone: +1 503 498 8145
Address:1161 NW Overton St
City: Portland
State: Oregon 97209
Country: United States
Website: https://www.evolvetogetherpdx.com/services.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: In-Home Fitness Trainer in Portland, OR Celebrates Decade of Success With Feature in National Redfin Blog

Tax Services in Chicago, IL Pioneer New Approach to Building Multi-Generational Wealth Through Strategic Investment and Tax Planning

CHICAGO, IL – Badu Tax Services has launched an innovative approach to wealth building that combines strategic tax planning with investment guidance, specifically designed to help clients establish multi-generational wealth. This integrated methodology addresses the growing demand for comprehensive financial strategies beyond traditional tax preparation.

The firm’s approach reflects founder Jeff Badu’s personal philosophy of financial abundance, developed through his journey from immigrant to millionaire entrepreneur. By applying these principles systematically, the company aims to transform how clients approach long-term financial planning.

“As a CPA, I wanted to share my knowledge of financial literacy beyond basic tax compliance,” explains Badu. “My goal is to inspire and support those who want to maximize their resources to create an abundant lifestyle, protect their finances, and ultimately reach their financial goals through strategic planning.”

The comprehensive program from the owner of a company that offers some of the best tax services in Chicago, IL includes personalized guidance on minimizing tax liability while strategically investing the resulting savings for long-term growth. This approach has attracted clients nationwide seeking sophisticated financial guidance.

Clients using the firm’s tax preparation services in Chicago, IL receive detailed analysis of their current financial positions along with tailored strategies for building sustainable wealth. The company’s expertise extends to both domestic and international investment opportunities.

The firm’s accounting services in Chicago, Illinois division complements this wealth-building approach by providing ongoing financial monitoring and reporting to ensure strategies remain aligned with changing economic conditions and client objectives.

With a team of experienced tax professionals in Chicago, IL, the company specializes in identifying often-overlooked tax advantages that can significantly impact long-term wealth accumulation. Their holistic perspective integrates real estate investments, retirement planning, and business structuring. For more information about building multi-generational wealth through strategic tax planning and investment, visit https://www.badutaxservices.com/ or contact Badu Tax Services directly to schedule a consultation with their nationwide team of financial experts.

Media Contact
Company Name: Badu Tax Services LLC
Contact Person: Jeff Badu
Email: Send Email
Phone: 773-819-5675
Address:4258 N Greenview Ave Ste 1E
City: Chicago
State: Illinois 60613
Country: United States
Website: http://badutaxservices.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tax Services in Chicago, IL Pioneer New Approach to Building Multi-Generational Wealth Through Strategic Investment and Tax Planning

Top Real Estate Listing Agent in Wesley Chapel, FL, Introduces Innovative Seller Strategy That Maximizes Property Value in Competitive Market

Wesley Chapel, FL – Michelle Moreno, a veteran with extensive real estate expertise, has unveiled an innovative selling strategy designed to help homeowners maximize their property values in today’s competitive market. This approach leverages precision and strategic planning to optimize home presentation, timing, and negotiation tactics.

As a highly regarded real estate listing agent in Wesley Chapel, FL, Moreno brings exceptional discipline to real estate transactions. Her selling framework incorporates comprehensive market analysis, strategic property enhancements, and tactical pricing strategies that have consistently achieved above-average returns for clients.

“My experience taught me the importance of meticulous planning and flawless execution,” said Michelle Moreno. “I’ve applied these same principles to develop a selling strategy that identifies a property’s unique strengths and positions it for maximum market appeal and value.”

The approach begins with an in-depth property assessment conducted by experienced Realtor agents in Wesley Chapel, FL who identify high-impact improvements that deliver the best return on investment. This precision-focused methodology continues through every stage of the selling process, from professional staging to strategic negotiation tactics.

As a dedicated real estate agent in Wesley Chapel, FL, Moreno’s background has instilled values like integrity, diligence, and attention to detail that prove invaluable when marketing properties. Her Graduate, Realtor Institute (GRI) certification further enhances her ability to navigate complex transactions with confidence.

“What sets my service apart is a commitment to treating each property as a unique mission,” Moreno explained. “As Realtors in Wesley Chapel, FL, we approach each listing with the same dedication and strategic thinking that has defined our careers.”

Moreno’s Military Relocation Professional (MRP) certification also provides her with specialized knowledge to assist military personnel and their families with housing solutions, a valuable asset in the Wesley Chapel community with its proximity to military installations.

Homeowners interested in learning how this innovative selling strategy can maximize their property value should visit https://keytosold.kw.com or contact Michelle Moreno directly to schedule a personalized property valuation and strategy consultation today.

Media Contact
Company Name: Key to Sold Team | Keller Williams Tampa Properties | Real Estate Agent in Wesley Chapel FL
Contact Person: Michelle Moreno
Email: Send Email
Phone: +1 813-523-6613
City: Wesley Chapel
State: Florida
Country: United States
Website: https://keytosold.kw.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Listing Agent in Wesley Chapel, FL, Introduces Innovative Seller Strategy That Maximizes Property Value in Competitive Market

Top Real Estate Agent in Pleasant View, UT Lists 4-Bedroom Home with Large Backyard and Updated Kitchen Features

Pleasant View, UT – A stunning 4-bedroom, 3-bathroom home featuring 2,690 square feet of living space is now available in Pleasant View’s desirable neighborhood. This exceptional property sits on 0.29 acres and offers modern amenities combined with energy-efficient features that make it an attractive option for today’s discerning homebuyers.

Richard Curtis, a top real estate agent in Pleasant View, UT, brings over 20 years of expertise to this exceptional listing. His extensive background includes new construction sales, foreclosure prevention, investment properties, and serving as a Principal Broker. Curtis understands the local market dynamics and what buyers seek in today’s competitive environment.

The home showcases impressive interior features including an updated kitchen with granite countertops, built-in dishwasher, and wet bar perfect for entertaining guests. With central air conditioning, smart thermostats, and a luxurious primary bath, the property provides comfort and convenience throughout every season. The home includes both carpet and tile flooring, along with bay box windows that flood the space with natural light, while video cameras and smart technology enhance security.

Energy efficiency takes center stage with solar panels and backup battery systems designed to significantly reduce monthly electric bills. The reverse osmosis water filtration system ensures clean, quality water throughout the home for drinking and cooking. Richard Curtis, Realtor in Pleasant View, UT recognizes this property’s exceptional value proposition, especially with its full basement adding substantial additional living space and storage options for growing families.

“This property is located in a desirable neighborhood with strong community appeal. The home is well-maintained and in excellent condition throughout. The solar panel system provides ongoing utility cost savings, delivering both environmental benefits and long-term financial value,” says Richard Curtis. The property’s outdoor features are equally impressive, with a large fenced backyard, covered patio, mature landscaping including fruit trees, and RV parking capability. As a trusted real estate listing agent in Pleasant View, UT, Curtis ensures buyers receive expert guidance throughout the process.

For buyers seeking quality construction, energy efficiency, and space to grow, this real estate agent in Pleasant View, UT recommends scheduling a private showing. Contact Richard Curtis today at http://richardcurtis.realtor/ to explore this exceptional property and begin your journey toward homeownership in Pleasant View’s thriving community.

Media Contact
Company Name: Richard Curtis – Equity Real Estate Agent in Pleasant View UT
Contact Person: Richard Curtis
Email: Send Email
Phone: +1 801 458 5428
Address:3802 North 650 West
City: Pleasant View
State: Utah 84414
Country: United States
Website: http://richardcurtis.realtor/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Agent in Pleasant View, UT Lists 4-Bedroom Home with Large Backyard and Updated Kitchen Features

2025 Beijing CBD Forum Annual Conference Kicks Off

On June 11, the 2025 Beijing CBD Forum Annual Conference commenced, held concurrently with the United Nations Development Programme (UNDP) Asia Mayors Forum. The conference will run until June 13.

Beijing CBD is the city’s “golden business card” and a vital gateway for the capital’s global engagement. During the forum, over 6,000 representatives from politics, business, and academia worldwide gathered in Beijing to explore international economic and trade cooperation. The opening ceremony, alongside the 2025 Beijing CBD Multinational Corporation Summit, the Beijing CBD Global Board Meeting, and four other flagship international events, as well as numerous parallel forums, were held simultaneously.

70% of Speakers Are International Guests, Representing Over 40 Countries and Regions

On the morning of June 11, the China World Hotel was filled with distinguished guests. Over 20 representatives from Asian cities, 30 delegates from international organizations and business associations, and more than 6,000 participants from the Global Alliance for Innovation in Business Districts and the China Business District Alliance attended the forum. Statistics show that 70% of the main forum speakers were international guests, with attendees hailing from over 40 countries and regions and spanning more than 10 core industries, sparking in-depth discussions across specialized fields. This diverse international participation infused the forum with global perspectives and cutting-edge ideas.

Centered on the permanent theme of “Dialogue with the World for Common Development,” the forum featured one opening ceremony (including the 2025 Beijing CBD Multinational Corporation Summit), four flagship international events, and multiple parallel forums.

During the opening ceremony’s achievements release session, Chaoyang District unveiled several high-quality development projects and outcomes. International business associations and global business district representatives jointly launched the “Building a Clean, Beautiful, and Sustainable World Together” initiative. Additionally, the “Belt and Road” Express Service Platform’s “CBD Lounge” was inaugurated. The forum also recognized the second batch of standing council members of the Beijing CBD Multinational Corporation Summit, establishing a new benchmark for foreign-funded enterprises based on headquarters prioritization and industry leadership.

Beijing CBD ranks as China’s top and the world’s seventh-largest business district. In 2024 alone, the CBD area added 10 new regional headquarters of multinational corporations, bringing the total to 122. Since 2000, the Beijing CBD Forum has evolved into a frontline platform for China’s global dialogue and a robust pillar for Beijing’s role as an international exchange hub.

UNDP Asia Mayors Forum Held Concurrently, Four Flagship Events to Boost Economic Cooperation

Beijing CBD is the most concentrated area for foreign-funded enterprises in the capital. The forum aims to foster international economic collaboration and attract investment. During the event, Beijing CBD will host four flagship international activities: the Beijing CBD Global Board Meeting Series, Government-Business Dialogue, Global Business Districts “Experience Beijing” Event, and Sino-Foreign Automakers Roundtable.

On June 12, the Beijing Municipal Commerce Bureau and the CBD Administrative Committee will co-host a policy-focused government-business dialogue on stabilizing foreign investment. The session will interpret the latest policies, address corporate needs, and facilitate exchanges to support foreign enterprises in China.

Held concurrently, the UNDP Asia Mayors Forum, themed “Collaborative Innovation: Co-Creating Low-Carbon and Sustainable Future Cities,” brings together global urban leaders, multinational executives, international organization representatives, and academic experts. Guided by the UN Sustainable Development Goals (SDGs), the forum emphasizes international cooperation, multi-stakeholder collaboration, and financial and technological innovation to drive urban sustainability.

Beijing is accelerating its development as a global green economy leader. As a high-density economic hub, the CBD plays a critical role in energy conservation, renewable energy adoption, and efficiency improvements.

In recent years, Beijing CBD has implemented policies like the “Measures to Promote High-Quality Development of Beijing CBD” and the “CBD Building Quality Grading Standards” to support green industries and enhance smart, eco-friendly services. Currently, LEED Gold or higher-certified buildings in the area span 4.9 million square meters.

Beijing CBD Elected Chair of Global Alliance for Innovation in Business Districts

Today, Beijing CBD stands among the world’s premier business districts, alongside Manhattan, La Défense, and Hong Kong’s Central. Hosting nearly 16,000 foreign entities, it is Beijing’s most concentrated area for multinational regional headquarters. The CBD Administrative Committee continues to refine its business-friendly environment.

Initiatives like the “CBD Investment Service Center” streamline administrative processes, while the “Headquarters Growth Plan” assists companies like BMW China and Toyota Financial Services in obtaining regional headquarters status. In May 2025, the “Beijing CBD Foreign Investment Service Center” launched, positioning itself as the “first stop for foreign enterprises entering China.”

Through institutional innovation, Beijing CBD advances the integrated business environment of the Beijing-Tianjin-Hebei region. In June 2023, the “Beijing CBD-Tianjin Port Collaborative Service Center” was established with Tianjin Port Group and Beijing Customs, offering one-stop logistics services.

Aligned with global trade standards, Beijing CBD is building a market-oriented, law-based, and internationalized business ecosystem. It has attracted top arbitration bodies like the Beijing Arbitration Commission and the Singapore International Arbitration Centre.

In 2024, Beijing CBD was elected chair of the Global Alliance for Innovation in Business Districts, enhancing Beijing’s global influence. This year, multinationals like Aramco Asia and Hamamatsu Photonics have chosen the CBD for their global board meetings.

Chaoyang to Issue Consumption Vouchers, CBD Pop-Up Walkway Opens

Beijing CBD, home to landmarks like China World Mall, SKP, and Xiushui Street, is evolving into a trillion-yuan international commercial hub. During the forum, attendees and visitors can enjoy discounts across CBD’s retail spaces.

From June 13–15 (Friday–Sunday), a CBD Pop-Up Walkway will open at China World Summit Wing from 11 AM to 9 PM, featuring specialty products like Canadian ice wine, Thai cuisine, and Belgian skincare, alongside camping zones and stamp-collecting activities.

Chaoyang District will distribute ¥3.5 million in consumption vouchers for retail, supermarkets, F&B, and cultural-sports sectors.

The 2025 Beijing CBD Forum will host 50+ annual events, including a Hot Dog Festival, Coffee Festival, Beijing Spicy Festival, and Xiushui Street Fashion Show. Details are available on the official WeChat account “Beijing CBD Window.”

Media Contact
Company Name: Beijing CBD Window
Contact Person: Rain Guo
Email: Best2008@gmail.com
Country: China
Website: https://english.beijing.gov.cn/whatson/events/forum/202506/t20250603_4103984.html

Diabetes Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight

“Diabetes Clinical Trials”
Diabetes Companies are vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.

(Albany, USA) DelveInsight’s, “Diabetes Pipeline Insight 2025” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight’s comprehensive report today! @ Diabetes Pipeline Outlook

 

Key Takeaways from the Diabetes Pipeline Report

  • In April 2025, Gan & LEE Pharmaceuticals announced a study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Degludec with or without Non-Insulin Antidiabetic Agents in subjects with Type 2 Diabetes Mellitus (T2DM) treated with basal insulin.
  • In March 2025, Dong-AST Co. Ltd announced a study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control.
  • In March 2025, Novo Nordisk A/S announced a study compares 2 medicines for type 1 and type 2 diabetes – faster aspart (a new medicine) and insulin aspart (a medicine doctors can already prescribe). Participants will either get faster aspart or insulin aspart (NovoRapid®) – which treatment is decided by chance.
  • DelveInsight’s Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
  • The leading Diabetes Companies such as vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
  • Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103, and others.

 

Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs

 

Emerging Diabetes Drugs Profile

  • Cadisegliatin: vTv Therapeutics

Cadisegliatin, also known as TTP399, is an innovative oral medication developed by vTv Therapeutics, designed as a liver-selective glucokinase activator. It aims to serve as an adjunctive therapy to insulin for individuals with type 1 diabetes (T1D). This drug has been recognized for its potential to improve glycemic control by enhancing hepatic glucose uptake and glycogen storage independently of insulin, addressing a critical need in diabetes management. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of Diabetes.

  • LY-3209590: Eli Lilly and Company

Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes.

  • THDB0206: Tonghua Dongbao Pharmaceutical

BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the treatment of Diabetes. BC Lispro is designed to restore early-phase insulin secretion, which is often impaired in diabetic patients. This insulin analog utilizes a new formulation technology that allows for rapid absorption and action, mimicking the physiological pattern of insulin secretion after meals. Such characteristics are expected to reduce the risk of late postprandial hypoglycemia, providing patients with greater flexibility in managing their insulin injections. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of Diabetes.

  • CPL207280: Celon Pharma

CPL207280 is a novel G-protein-coupled receptor 40 (GPR40) agonist under development for the treatment of Diabetes. CPL207280 acts as an agonist for GPR40, a receptor that plays a crucial role in enhancing glucose-stimulated insulin secretion from pancreatic beta cells. This mechanism is particularly beneficial for T2D patients, as it can improve glycemic control without the risk of hypoglycemia, a common side effect associated with other diabetes medications. Currently, the drug is in the Phase II stage of development to treat Diabetes.

  • XW014: Sciwind Biosciences

XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes.

  • KN056: Suzhou Alphamab Co., Ltd.

KN-056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd. for the treatment of Diabetes. KN-056 functions as a GLP-1R modulator, which means it targets the glucagon-like peptide-1 receptor. GLP-1 is a hormone that plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. By modulating the GLP-1 receptor, KN-056 aims to improve glycemic control in patients with Diabetes. Currently, the drug is in the Phase I stage of its clinical trial for the treatment of Diabetes.

 

The Diabetes Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Diabetes with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment.
  • Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market

 

Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight’s detailed report now! @ New Diabetes Drugs and Medication

 

Diabetes Companies

vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.

 

The Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Diabetes Products have been categorized under various Molecule types such as,

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Diabetes Market Drivers and Barriers

 

Scope of the Diabetes Pipeline Report

  • Coverage- Global
  • Diabetes Companies- vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
  • Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others.
  • Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diabetes: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Diabetes– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Cadisegliatin: vTv Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid-Stage Products (Phase II)
  11. CPL207280: Celon Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. KN056: Suzhou Alphamab Co., Ltd.
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Diabetes Key Companies
  21. Diabetes Key Products
  22. Diabetes- Unmet Needs
  23. Diabetes- Market Drivers and Barriers
  24. Diabetes- Future Perspectives and Conclusion
  25. Diabetes Analyst Views
  26. Diabetes Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetes Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight

Liver Fibrosis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Epidemiology, Revenue, Statistics, Medication, and Companies by DelveInsight

“Liver Fibrosis Drugs Market”
Liver Fibrosis Companies are Beijing Continent Pharmaceutical, Gilead Sciences, Galmed R&D, Hepion Pharmaceuticals, HK inno.N Corporation, Conatus Pharmaceuticals, Dr. Falk Pharma GmbH, InterMune, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Akero Therapeutics, Inc, Pfizer, AstraZeneca, and others.

(Albany, USA) DelveInsight’s “Liver Fibrosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Liver Fibrosis, offering comprehensive insights into the Liver Fibrosis revenue trends, prevalence, and treatment landscape. The report delves into key Liver Fibrosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Liver Fibrosis therapies. Additionally, we cover the landscape of Liver Fibrosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Liver Fibrosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Liver Fibrosis space.

 

To Know in detail about the Liver Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Fibrosis Market Forecast

 

Some of the key facts of the Liver Fibrosis Market Report:

  • The Liver Fibrosis market size was valued ~USD 2,308 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In 2023, the United States represented the largest portion of the Liver Fibrosis market, comprising around 79% of the total market size across the 7MM, surpassing other key regions such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
  • In 2023, Germany led the EU countries with the highest Liver Fibrosis market size, reaching approximately USD 99 million, while Spain had the smallest market size at around USD 59 million.
  • In 2023, supportive therapies in Japan represented a market size of approximately USD 113 million.
  • Madrigal Pharmaceuticals aims to roll out REZDIFFRA across Europe starting with Germany in the second half of 2025, pending EMA approval for REZDIFFRA, making it the first authorized therapy for MASH-related liver fibrosis in the region. Furthermore, updated two-year data from the MAESTRO-NAFLD-1 trial, released in February 2025, indicate possible benefits for patients with compensated MASH cirrhosis, suggesting an expanded scope of clinical effectiveness.
  • In February 2025, Sagimet announced lipidomic data from the Phase IIb FASCINATE-2 trial, focusing on triglycerides and LDL cholesterol in advanced fibrosis, which will be presented at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium. The US FDA granted denifanstat Breakthrough Therapy (BTD) and Fast Track Designation (FTD) for non-cirrhotic MASH with moderate to advanced fibrosis.
  • In January 2025, Alentis Therapeutics, a clinical-stage biotech company focused on developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced promising topline results from two clinical trials of lixudebart (ALE.F02), a monoclonal antibody designed to reverse organ fibrosis.
  • In January 2025, Akero Therapeutics has released preliminary topline results from its Phase IIb SYMMETRY study, evaluating efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, caused by metabolic dysfunction-associated steatohepatitis (MASH). This placebo-controlled, multicenter, double-blind, dose-ranging, randomized trial included adult participants with the condition. The primary efficacy endpoint measured the proportion of patients achieving at least a one-stage fibrosis improvement by week 36 without MASH progression.
  • In November 2024, Boston Pharmaceuticals reported positive Phase II data for BOS-580 in F2/F3 MASH at AASLD 2024. The treatment showed significant improvement in fibrosis (≥1 stage) with no worsening of MASH after 24 weeks. Two-thirds of patients treated with BOS-580 achieved significant MASH resolution without worsening fibrosis, compared to placebo. The Phase II trial also showed reductions in liver injury markers, fibrosis, and improvements in metabolic health. BOS-580 has demonstrated low discontinuation rates in clinical trials, with gastrointestinal issues being the most common side effects. In June 2024, data presented at EASL Congress 2024 highlighted significant improvements in lipid profiles with BOS-580 treatment.
  • In October 2024, Boehringer Ingelheim initiated the LIVERAGE trials, including LIVERAGE for MASH with fibrosis and LIVERAGE-Cirrhosis for MASH with cirrhosis. The US FDA granted Survodutide BTD for non-cirrhotic MASH with fibrosis, while the European Medicines Agency (EMA) included it in its Priority Medicines (PRIME) scheme for NASH. Boehringer Ingelheim and Zealand Pharma received US FDA support, highlighting Survodutide’s potential to address unmet needs in MASH treatment.
  • The anticipated introduction of new therapies, including Efruxifermin (AKR-001), Lanifibranor, and Aramchol, is expected to significantly impact the liver fibrosis market size in the coming years.
  • Key Liver Fibrosis Companies: Beijing Continent Pharmaceutical, Gilead Sciences, Galmed R&D, Hepion Pharmaceuticals, HK inno.N Corporation, Conatus Pharmaceuticals, Dr. Falk Pharma GmbH, InterMune, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Akero Therapeutics, Inc, Pfizer, AstraZeneca, and others
  • Key Liver Fibrosis Therapies: Hydronidone capsules, Simtuzumab, Aramchol, Rencofilstat, oltipraz, IDN-6556, ZED1227, interferon gamma-1b, BMS-986263, peginterferon alfa-2b (SCH 54031), Efruxifermin, PF-06865571, Zibotentan + dapagliflozin, and others
  • The Liver Fibrosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Fibrosis pipeline products will significantly revolutionize the Liver Fibrosis market dynamics.
  • According to DelveInsight’s assessment, the estimated total number of diagnosed prevalent cases of liver fibrosis in the 7MM was approximately 19 million in 2023.
  • In 2023, the United States recorded the highest number of diagnosed prevalent cases of liver fibrosis, with 9 million cases, and this figure is expected to increase in the future.
  • In 2023, Germany had the highest number of diagnosed prevalent cases of liver fibrosis among European countries, followed by Italy, while Spain had the fewest cases.
  • In 2023, Japan had around 2 million diagnosed prevalent cases of liver fibrosis, representing approximately 12% of the total cases in the 7MM.
  • In the US, individuals in the F1 stage of NASH were most impacted by liver fibrosis, with approximately 3 million cases reported in 2023, based on severity-specific diagnosed prevalent cases.
  • In 2023, the total diagnosed prevalent cases of NASH-related liver fibrosis in the EU4 and the UK were approximately 1 million.

 

Liver Fibrosis Overview

Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, in the liver as a result of chronic liver injury. It is a progressive condition that represents a response to liver damage caused by factors such as viral hepatitis (HBV or HCV), alcohol abuse, non-alcoholic fatty liver disease (NAFLD), autoimmune disorders, or exposure to toxins and certain medications.

Fibrosis occurs when repeated injury and inflammation trigger the activation of hepatic stellate cells, which produce fibrous scar tissue. Over time, the buildup of this scar tissue disrupts the liver’s architecture and impairs its ability to function, potentially progressing to cirrhosis, liver failure, or hepatocellular carcinoma.

In its early stages, liver fibrosis is often asymptomatic. As it advances, symptoms such as fatigue, abdominal discomfort, and signs of portal hypertension (e.g., varices, ascites) may develop.

Diagnosis typically involves blood tests, imaging techniques like elastography, and liver biopsy to assess fibrosis severity. The stage of fibrosis is graded on a scale, with advanced stages indicating cirrhosis.

Management focuses on treating the underlying cause, such as antiviral therapy for hepatitis or lifestyle changes for NAFLD. Emerging antifibrotic therapies are being explored, but early intervention remains critical to prevent irreversible liver damage.

 

Get a Free sample for the Liver Fibrosis Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/liver-fibrosis-market

 

Liver Fibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Liver Fibrosis Epidemiology Segmentation:

The Liver Fibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Liver Fibrosis
  • Prevalent Cases of Liver Fibrosis by severity
  • Gender-specific Prevalence of Liver Fibrosis
  • Diagnosed Cases of Episodic and Chronic Liver Fibrosis

 

Download the report to understand which factors are driving Liver Fibrosis epidemiology trends @ Liver Fibrosis Epidemiology Forecast

 

Liver Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Fibrosis market or expected to get launched during the study period. The analysis covers Liver Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on

market share.

The report also covers the Liver Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Liver Fibrosis Therapies and Key Companies

  • Hydronidone capsules: Beijing Continent Pharmaceutical
  • Simtuzumab: Gilead Sciences
  • Aramchol: Galmed R&D
  • Rencofilstat: Hepion Pharmaceuticals
  • oltipraz: HK inno.N Corporation
  • IDN-6556: Conatus Pharmaceuticals
  • ZED1227: Dr. Falk Pharma GmbH
  • interferon gamma-1b: InterMune
  • BMS-986263: Bristol-Myers Squibb
  • peginterferon alfa-2b (SCH 54031): Merck Sharp & Dohme LLC
  • Efruxifermin: Akero Therapeutics, Inc
  • PF-06865571: Pfizer
  • Zibotentan + dapagliflozin: AstraZeneca

 

Discover more about therapies set to grab major Liver Fibrosis market share @ Liver Fibrosis Treatment Landscape

 

Liver Fibrosis Market Drivers

  • Rising Prevalence of Chronic Liver Diseases
  • Advancements in Diagnostic Techniques
  • Ongoing Drug Development
  • Awareness Programs
  • Government Initiatives

 

Liver Fibrosis Market Barriers

  • High Treatment Costs
  • Lack of Approved Therapies
  • Slow Diagnosis in Early Stages
  • Regulatory Challenges
  • Patient Adherence Issues

 

Scope of the Liver Fibrosis Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Liver Fibrosis Companies: Beijing Continent Pharmaceutical, Gilead Sciences, Galmed R&D, Hepion Pharmaceuticals, HK inno.N Corporation, Conatus Pharmaceuticals, Dr. Falk Pharma GmbH, InterMune, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Akero Therapeutics, Inc, Pfizer, AstraZeneca, and others
  • Key Liver Fibrosis Therapies: Hydronidone capsules, Simtuzumab, Aramchol, Rencofilstat, oltipraz, IDN-6556, ZED1227, interferon gamma-1b, BMS-986263, peginterferon alfa-2b (SCH 54031), Efruxifermin, PF-06865571, Zibotentan + dapagliflozin, and others
  • Liver Fibrosis Therapeutic Assessment: Liver Fibrosis current marketed and Liver Fibrosis emerging therapies
  • Liver Fibrosis Market Dynamics: Liver Fibrosis market drivers and Liver Fibrosis market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Liver Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Liver Fibrosis Market Access and Reimbursement

 

To know more about Liver Fibrosis companies working in the treatment market, visit @ Liver Fibrosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Liver Fibrosis Market Report Introduction

2. Executive Summary for Liver Fibrosis

3. SWOT analysis of Liver Fibrosis

4. Liver Fibrosis Patient Share (%) Overview at a Glance

5. Liver Fibrosis Market Overview at a Glance

6. Liver Fibrosis Disease Background and Overview

7. Liver Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Liver Fibrosis

9. Liver Fibrosis Current Treatment and Medical Practices

10. Liver Fibrosis Unmet Needs

11. Liver Fibrosis Emerging Therapies

12. Liver Fibrosis Market Outlook

13. Country-Wise Liver Fibrosis Market Analysis (2020–2034)

14. Liver Fibrosis Market Access and Reimbursement of Therapies

15. Liver Fibrosis Market Drivers

16. Liver Fibrosis Market Barriers

17. Liver Fibrosis Appendix

18. Liver Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Related Reports:

Liver Fibrosis Pipeline

Liver Fibrosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key liver fibrosis companies, including Galmed Research and Development, Ltd, AstraZeneca, Galectin Therapeutics, Resolution Therapeutics, AdAlta, Novo Nordisk A/S, Sagimet Biosciences Inc., Hepion Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Inipharm, GAT Therapeutics, TiumBio, INVENT Pharmaceuticals, SFA Therapeutics, among others.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Liver Fibrosis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Epidemiology, Revenue, Statistics, Medication, and Companies by DelveInsight